BrainsWay Ltd. (NASDAQ:BWAY – Get Free Report) was the target of a large drop in short interest in the month of June. As of June 30th, there was short interest totalling 36,300 shares, a drop of 14.8% from the June 15th total of 42,600 shares. Based on an average daily trading volume, of 61,400 shares, the days-to-cover ratio is currently 0.6 days.
BrainsWay Price Performance
Shares of NASDAQ BWAY traded up $0.34 during midday trading on Monday, reaching $6.90. 72,455 shares of the stock traded hands, compared to its average volume of 96,327. The company’s 50 day moving average is $5.99 and its 200 day moving average is $5.97. BrainsWay has a one year low of $2.17 and a one year high of $7.61. The stock has a market capitalization of $115.02 million, a PE ratio of -76.55 and a beta of 1.24.
BrainsWay (NASDAQ:BWAY – Get Free Report) last issued its quarterly earnings results on Wednesday, May 8th. The company reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.02. BrainsWay had a negative return on equity of 3.98% and a negative net margin of 4.83%. The company had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.65 million. As a group, equities analysts forecast that BrainsWay will post 0.02 EPS for the current year.
Institutional Trading of BrainsWay
Analyst Upgrades and Downgrades
Several equities analysts have recently issued reports on BWAY shares. Oppenheimer boosted their target price on BrainsWay from $10.00 to $11.00 and gave the company an “outperform” rating in a research note on Thursday, May 9th. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of BrainsWay in a research report on Wednesday, June 5th.
Get Our Latest Research Report on BWAY
About BrainsWay
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
See Also
- Five stocks we like better than BrainsWay
- What is Forex and How Does it Work?
- Automaker’s Bold Move to an EV Future: Is It Time to Buy Stock?
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Massive Breakout: This ETF Signals Big Gains for Small-Cap Stocks
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Major Gaming Stock to Watch: Why It’s a Safe Bet Now
Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.com's FREE daily email newsletter.